A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Standard taxane therapy|DRUG: capecitabine [Xeloda]|DRUG: trastuzumab [Herceptin]
Sponsor: Hoffmann-La Roche